Family History Influences Penetrance of Hereditary Cancers
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 25, 2023 -- For individuals with a pathogenic variant in the major genes responsible for hereditary breast cancer or Lynch syndrome, having a first-degree family history is associated with increased cancer risk, according to a study published online Sept. 14 in eClinicalMedicine.
Leigh Jackson, Ph.D., from the University of Exeter College of Medicine and Health in the United Kingdom, and colleagues analyzed 454,712 U.K. Biobank participants to examine how penetrance of familial cancer syndromes varies with family history. Participants with a self-reported family history of breast or colorectal cancer and a pathogenic/likely pathogenic variant in the major genes responsible for hereditary breast cancer or Lynch syndrome were identified.
The researchers found that women with a pathogenic BRCA1 or BRCA2 variant had an increased breast cancer risk, which was higher for those with a first-degree family history versus those without (relative hazards, 10.3 and 7.8 versus 7.2 and 4.7). Those with versus without a family history also had higher penetrance to age 60 years (44.7 and 24.1 percent versus 22.8 and 17.9 percent). In Lynch syndrome, a similar pattern was observed, with an increased risk for colorectal cancer that was significantly higher in those with versus without a family history among individuals with a pathogenic MLH1, MSH2, or MSH6 variant (relative hazards, 35.6, 48.0, and 9.9 versus 13.0, 15.4, and 7.2). Carriers of a pathogenic MLH1 or MSH2 variant with family history had higher penetrance to age 60 years than those without a family history (30.9 and 38.3 percent versus 20.5 and 8.3 percent).
"Having an affected first-degree relative may increase the penetrance of pathogenic variants for breast and colorectal cancer in two hereditary cancer syndromes," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.